{"result": "(\"entity\"<|>HEMATOLOGICAL MALIGNANCIES<|>EVENT<|>Hematological malignancies are cancers that affect blood, bone marrow, and lymph nodes, often treated with hematopoietic stem cell transplants.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support is critical for patients undergoing hematopoietic stem cell transplants to prevent malnutrition and support recovery.)\n##\n(\"entity\"<|>IMMUNE RECOVERY<|>EVENT<|>Immune recovery refers to the process of regaining immune function after a hematopoietic stem cell transplant, which is crucial for patient health.)\n##\n(\"entity\"<|>APLASIA<|>EVENT<|>Aplasia is a condition where the bone marrow fails to produce adequate blood cells, often occurring after a hematopoietic stem cell transplant.)\n##\n(\"entity\"<|>INFECTION PREVENTION<|>EVENT<|>Infection prevention is a critical aspect of care for patients in aplastic phases post-transplant to avoid complications.)\n##\n(\"entity\"<|>NUTRITIONAL STATUS<|>EVENT<|>Nutritional status refers to the overall health and nutrition of a patient, which is particularly important before and after a hematopoietic stem cell transplant.)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>HEMATOLOGICAL MALIGNANCIES<|>Hematopoietic stem cell transplants are often used as a treatment for hematological malignancies<|>9)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>NUTRITIONAL SUPPORT<|>Nutritional support is essential during the recovery phase of hematopoietic stem cell transplant to ensure patient health<|>8)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>IMMUNE RECOVERY<|>Immune recovery is a key focus after hematopoietic stem cell transplant to restore the patient's immune system<|>8)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>APLASIA<|>Aplasia is a common condition following hematopoietic stem cell transplant that requires careful monitoring<|>6)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>INFECTION PREVENTION<|>Infection prevention measures are critical during the aplastic phase after a hematopoietic stem cell transplant<|>8)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>NUTRITIONAL STATUS<|>Nutritional status is a significant factor influencing recovery outcomes after hematopoietic stem cell transplant<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ulas obtenidas de cordón tienen un fenotipo diferente, son más inmaduras funcionalmente y presentan un mayor potencial proliferativo.\n\nIndependientemente de la procedencia de las células hematológicas, estas se trasplantan mediante inyección al torrente circulatorio del receptor. Previamente, el candidato a trasplante se somete a un régimen de acondicionamiento mieloablativo, para vaciar su médula de células hematológicas propias, que son potencialmente causantes de rechazo. Las células inyectadas se establecen a nivel de la médula ósea. Después de una fase de aplasia medular, se inicia la recuperación de las series hematológicas.\n\nDesde un punto de vista académico, el trasplante se puede dividir en varias etapas. El conocimiento de estas fases tiene interés porque el riesgo de desnutrición y el abordaje nutricional es diferente.\n\n## 2.1. Fase de obtención de productos hematopoyéticos\n\nLos productos hematopoyéticos necesarios para el trasplante se obtienen con anterioridad al acondicionamiento. Una vez obtenidos, se conservan generalmente en frío, hasta ser posteriormente utilizados.\n\n## 2.2. Fase de manipulación ex vivo del injerto\n\nUna vez que el trasplante se va a realizar, los productos hematopoyéticos se deben manipular para eliminar las células neoplásicas y los linfocitos T del donante, y concentrar los productos mediante selección positiva o aumentar su cantidad con técnicas de expansión. Además, en el alotrasplante con incompatibilidad mayor del grupo ABO es necesario eliminar los hematíes por centrifugación o realizar plasmaféresis.\n\n## 2.3. Fase de acondicionamiento\n\nConsiste en la administración de dosis altas de quimioterapia, radioterapia o ambas al candidato de trasplante. Tiene varios objetivos. En primer lugar, eliminar las células hematopoyéticas y tumorales, si existen, del receptor. En segundo lugar, crear espacio medular para las células nuevas procedentes del injerto. Por último, se persigue evitar el rechazo con la inmunosupresión en el trasplante alogénico y en el xenogénico.\n\n## 2.4. Fase de administración de los productos hematopoyéticos\n\nSupone el denominado día 0 del trasplante. Consiste en la administración de los productos hematopoyéticos al receptor, a través de un catéter endovenoso, infundiéndolos a sangre periférica.\n\n## 2.5. Fase aplásica\n\nEs la fase en la que el paciente, después de administrados los productos hematopoyéticos, permanece en aplasia medular. En este momento lo más importante son las medidas de soporte. Se adoptan medidas para evitar la infección, entre ellas se mantiene al paciente en régimen de aislamiento ambiental y se administran antibióticos. Además, se efectúa soporte con transfusiones de hematíes y plaquetas. En esta etapa la vigilancia nutricional es importante, requiriendo en algunos casos soporte nutricional.\n\n## 2.6. Fase de recuperación hematológica\n\nA partir del día 10-14 desde la administración del injerto, pueden aparecer células hematopoyéticas en la médula ósea del receptor. Esto se manifiesta como elevación de las cifras de reticulocitos, leucocitos y finalmente plaquetas en sangre periférica. La recuperación hematológica es más precoz si el trasplante es de sangre periférica frente al de médula ósea.\n\nDesde el punto de vista nutricional, esta etapa es importante, porque, una vez iniciada la aparición de leucocitos, pueden comenzar los primeros síntomas y signos de EICH en el trasplante alogénico.\n\n## 2.7. Fase de reconstitución inmune\n\nEn esta etapa se van adquiriendo las defensas del receptor. Así, la IgE aumenta en el primer mes postrasplante, pero la producción de IgG e IgA no se recupera hasta los 6-18 meses.\n---\n## BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\nDurante los primeros 6 meses después del trasplante, se observa un número disminuido de células CD4+, con células NK y CD8+ normales o aumentadas, y respuesta deficiente de los linfocitos T a la fitohemaglutinina.\n\n### 3. Objetivos nutricionales\n\nComo se ha señalado anteriormente, el trasplante de células hematopoyéticas se utiliza para el tratamiento, tanto de enfermedades congénitas como adquiridas, y dentro de estas últimas para patologías tumorales o no tumorales. En general, el estado nutricional de los candidatos a este tipo de trasplante es bueno, incluso en los pacientes con tumores de origen hematológico. Sin embargo, los enfermos con tumores sólidos suelen estar previamente desnutridos². El empeoramiento del estado de nutrición antes\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>EVENT<|>Hematopoietic stem cell transplant is a medical procedure used to treat various diseases, including congenital and acquired conditions, particularly hematological malignancies.)\n##\n(\"entity\"<|>BLOQUE NUTRICIÓN EN ONCOLOGÍA<|>ORGANIZATION<|>Block focused on nutritional aspects in oncology, particularly during the recovery phase post-transplant.)\n##\n(\"entity\"<|>CD4+ CELLS<|>PERSON<|>CD4+ cells are a type of immune cell that are often monitored in patients post-transplant for immune recovery.)\n##\n(\"entity\"<|>NK CELLS<|>PERSON<|>Natural Killer (NK) cells are a type of immune cell that may be present or increased in patients after hematopoietic stem cell transplant.)\n##\n(\"entity\"<|>CD8+ CELLS<|>PERSON<|>CD8+ cells are another type of immune cell that can be normal or increased in patients following a hematopoietic stem cell transplant.)\n##\n(\"entity\"<|>LEUKOCYTES<|>PERSON<|>Leukocytes are white blood cells that are crucial for immune response and are monitored during recovery after a transplant.)\n##\n(\"entity\"<|>RETICULOCYTES<|>PERSON<|>Reticulocytes are immature red blood cells that indicate recovery of hematopoiesis post-transplant.)\n##\n(\"entity\"<|>PLATELETS<|>PERSON<|>Platelets are blood components that are important for clotting and are monitored during the recovery phase after a transplant.)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>BLOQUE NUTRICIÓN EN ONCOLOGÍA<|>Nutritional management is critical during the recovery phase of hematopoietic stem cell transplant, as outlined in the oncology nutrition block<|>8)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>CD4+ CELLS<|>Monitoring CD4+ cells is essential for assessing immune recovery after hematopoietic stem cell transplant<|>7)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>NK CELLS<|>NK cells are important in the immune response and their levels are observed post-transplant<|>7)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>CD8+ CELLS<|>CD8+ cells are monitored for immune recovery in patients after hematopoietic stem cell transplant<|>7)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>LEUKOCYTES<|>Leukocyte levels are critical indicators of recovery following a hematopoietic stem cell transplant<|>7)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>RETICULOCYTES<|>Reticulocyte counts are used to assess the recovery of red blood cell production after transplant<|>7)\n##\n(\"relationship\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>PLATELETS<|>Platelet counts are monitored to ensure proper recovery and prevent bleeding complications post-transplant<|>7)\n<|COMPLETE|>"}]}